Patient-reported outcomes with tarlatamab in extensive-stage small cell lung cancer after platinum-based chemotherapy: results from the phase 3 DeLLphi-304 trial.
Lung CancerAug 13, 2026 (epub)
Giannis Mountzios, Philip E Lammers, Longhua Sun et al.
✦ AI-curated · Sources linked
In 30 seconds
The phase 3 DeLLphi-304 trial evaluated patient-reported outcomes (PROs) in adults with extensive-stage small cell lung cancer (ES-SCLC) receiving tarlatamab versus standard-of-care chemotherapy after platinum-based therapy. Results showed that tarlatamab led to greater improvements in symptoms and health-related quality of life, with notable differences in chest pain (19% vs 10%) and cough (35% vs 26%) at 19 weeks.
Key findings
- 19% of tarlatamab patients reported improvement in chest pain compared to 10% in SoC.
- 35% of tarlatamab patients experienced improvement in cough versus 26% in SoC.
- Tarlatamab delayed deterioration in symptoms and physical functioning compared to SoC.
- Patients on tarlatamab reported being less bothered by treatment side effects over time.
Why it matters
The findings highlight the potential of tarlatamab to enhance patient quality of life and symptom management in a population with significant treatment challenges, suggesting it may be a valuable option in the therapeutic landscape for ES-SCLC.